A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate Binder in Dialysis Patients

NCT01464190 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

659

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Kidney Disease Requiring Chronic Dialysis

Interventions

DRUG: PA21 (2.5 g tablet containing 500 mg iron)
DRUG: Sevelamer carbonate

Sponsor

Vifor Pharma

Collaborators

[object Object]